David G. Watumull, President and CEO of Cardax, Inc, discusses the company’s plans to create a new platform for products in the consumer health and pharmaceutical markets based on the delivery of nature-identical astaxanthin.
ADVANCED DELIVERY DEVICES – How Data Hubs & Smart Devices Are Enabling the Rise of Therapeutic Ecosystems
Stephen Allan discusses how unique collaborations between tech and biotech reflect a new paradigm in how therapeutics are being commercialized and marketed under the new pay-for-performance healthcare model.
Michael Hooven, CEO of Enable Injections, discusses his vision for the company and how it intends to create marketleading biologics delivery devices that meet the most pressing needs of pharmaceutical companies while enabling easy patient self-administration for significant cost-savings.
NANOSCALE COMPLEXES – A Novel Nanotechnology-Based Platform to Optimize Combination Cancer Therapies: Rational Development & Improved Delivery Using CombiPlex®
Barry D. Liboiron, PhD; Arthur C. Louie, MD; et al describe how CombiPlex addresses the challenges facing the traditional development path of many contemporary drug combinations and provide clinical proof-of-principle evidence that this approach can yield marked improvements in efficacy and patient outcomes.
Kevin James and Kevin Gainer of BCC Research indicate the development of the market for combination products is closely related to the drug delivery systems sector, which represents a vast area of research and the demand for sophisticated drug delivery devices behind many novel product developments.
EXECUTIVE INTERVIEW – Unither Pharmaceuticals: Premeasured Dosage Forms to Improve Medication Adherence
Eric Goupil, CEO Unither Pharmaceuticals, speaks frankly about medication adherence, Unither’s technology, and some of the challenges that they face today.
Lisa A. Dick, PhD, describes how microneedle technology is being applied in two new transdermal systems using solid and hollow microneedles, which have the ability to deliver small molecules as well as biologics, opening up the potential for self-administration of a broad array of APIs
Divyaa Ravishankar, MS, indicates LOC-based devices are an integration of multiple disciplines and the miniaturization of the major laboratory procedures. Recently, these devices are branching into additional aspects of healthcare, such as drug delivery, stem cell, environmental monitoring, and synthetic biology.
Samuel D. Trohman, MBA, Joey L. Glassco, Elena Draganoiu, PhD, and Carey Boyum present developmental and commercial examples of non-biodegradable drug-eluting devices, along with the versatile properties of thermoplastic polyurethanes for the development of effective drug delivery systems.
FORMULATION DEVELOPMENT TECHNOLOGY – A Novel Drug Delivery System That Offers Zero-Order/Near Zero-Order Release Profile of Low-Dosage Strength Tablets Containing Highly Soluble Actives
Thomas B. Gold, PhD, was awarded a US patent; the intellectual property centers on formulation development technology that allows for the steady, continuous release of API over a particular duration of time to mitigate variations or spikes in therapeutic benefit.
EXCLUSIVE ONLINE CONTENT
Enable Injections, Inc. recently announced it has entered into a multi-product development agreement with Sanofi S.A.
AptarGroup, Inc. recently announced it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million.
Sol-Gel Technologies, Ltd. recently announced it has entered into a seventh collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc for the development, manufacturing, and commercialization of two new generic formulations of antibiotic foams.
Medherant Limited, the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch technology, recently announced a new $2.5-million investment.
Bone Sci Bio introduces PeptOss, a novel solution for bone treatment. The new product promotes formation and repair of bone tissue and enables controlled delivery of drugs, such as antibiotics or chemotherapy, directly to the bone, for various orthopedic and dental applications.